Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Multi-vitamins, HAART and HIV/AIDS in Uganda

This study has been completed.
Makerere University
Infectious Disease Institute, Kampala, Uganda
Information provided by (Responsible Party):
Wafaie Fawzi, Harvard School of Public Health Identifier:
First received: October 15, 2010
Last updated: May 20, 2014
Last verified: May 2014

The investigators are conducting a double-blind, placebo controlled,randomized trial of multivitamin supplements(containing B-vitamins, C, and E) to determine their efficacy in slowing disease progression, indicated by increased CD4 count, weight gain, and improved quality of life, and decreased morbidity, mortality, and drug-related adverse events (i.e. peripheral neuropathy, anemia, and diarrhea).

The investigators hypothesize that daily multivitamin supplementation will: (1) improve immune reconstitution; (2) improve weight gain, and (3) improve quality of life.

Condition Intervention Phase
Dietary Supplement: Multivitamin supplements B,C and E
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multi-vitamins, HAART and HIV/AIDS in Uganda

Resource links provided by NLM:

Further study details as provided by Wafaie Fawzi, Harvard School of Public Health:

Primary Outcome Measures:
  • Weight Gain [ Time Frame: 18 months ]
  • Immune Reconstitution [ Time Frame: 18 months ]
    Immune Reconstitution is measured by change in CD4 cell count

  • Improved Quality of Life [ Time Frame: 18 months ]

Secondary Outcome Measures:
  • New or recurrent disease progression event [ Time Frame: 18 months ]
  • Reduce the probability of changing drug therapy (indicated by switching from first- to second-line therapy) [ Time Frame: 18 months ]
  • Reduce HAART-associated adverse events (indicated by incident peripheral neuropathy, severe anemia, or diarrhea). [ Time Frame: 18 months ]

Estimated Enrollment: 400
Study Start Date: April 2010
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Multivitamins (B,C,E) Dietary Supplement: Multivitamin supplements B,C and E
One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
Placebo Comparator: Placebo Dietary Supplement: Multivitamin supplements B,C and E
One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months

Detailed Description:

Antiretroviral therapy, gradually becoming the standard of care in developing countries, confers enormous benefits and yet substantial morbidity remains in human immunodeficiency virus (HIV) positive populations. Multivitamin supplements have immune-enhancing effects, and supplements were found to improve immunologic status and reduce morbidity and mortality among HIV-positive Tanzanian women in pre-highly active anti-retroviral therapy (HAART) stages of disease. These supplements are thought to be required to restore adequate nutrient levels in the context of HIV infection.

This study will enroll 400 men and women in the Kampala district of Uganda, who are receiving or have recently initiated HAART. At baseline and monthly thereafter, research physicians and nurses at study clinics will assess each participant's clinical status and undertake study procedures. Each participant will be followed for 18 months, or until his/her death or loss to follow-up. Home visits will be conducted if participants miss their scheduled clinic appointments. We will perform nutritional assessments (anthropometry and dietary intake) at enrollment and several follow-up points, and laboratory measurements (CD4 cell counts and complete blood counts) every six months.

Importantly, all study participants will continue receiving the standard of care according to national guidelines for the entire study period. Multivitamins could be a low-cost, adjunct therapy for helping to alleviate disease burden and elevate quality of life in HIV-infected individuals on HAART. At the same time, their efficacy could help preserve limited drug regimens in developing settings by postponing the need for switches to second line regimens of HAART.

Our proposal represents a collaboration between the Harvard School of Public Health, Infectious Disease Institute and Makerere University School of Public Health in Kampala, Uganda.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • men or women aged >=18 years old
  • HIV-positive
  • initiating anti-retroviral therapy at the time of randomization or have been on highly active anti-retroviral therapy (HAART) for no more than 6 months
  • have no intention of migrating, or re-locating >= 20 km outside of the Infectious Disease Institute (IDI), or Kiswa Health Center within the next 18 months after enrollment
  • agree to allow home visit(s) and subsequent follow-up contacts as part of the study
  • provide written informed consent

Exclusion Criteria:

  • pregnant Women
  • individuals from whom we are unable to obtain written informed consent will be excluded from the study. For example, patients that are extremely ill and unable to consent will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01228578

Makerere University School of Public Health / Infectious Disease Institute
Kampala, Uganda
Sponsors and Collaborators
Harvard School of Public Health
Makerere University
Infectious Disease Institute, Kampala, Uganda
Principal Investigator: Wafaie W Fawzi, MD,MPH,DrPH Harvard School of Public Health
Principal Investigator: David Guwatudde, MPH, PhD Makerere University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Wafaie Fawzi, Principal Investigator, Harvard School of Public Health Identifier: NCT01228578     History of Changes
Other Study ID Numbers: HD060333-01
Study First Received: October 15, 2010
Last Updated: May 20, 2014

Keywords provided by Wafaie Fawzi, Harvard School of Public Health:
Immune reconstitution
Weight Gain
Quality of Life processed this record on May 25, 2017